StreetInsider.com News Articles

Form 8-K Voyager Therapeutics, For: Oct 20

Wed, 21 Oct 2026 08:07:00 -0400

si-local-file:///var/storage/secattach/20261021/27213489.html

Voyager Therapeutics names Robin Swartz president, plans CEO shift

Wed, 21 Oct 2026 08:02:16 -0400

Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced that its board of directors has appointed Robin Swartz as president, effective October 20, 2026, with plans for her to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as chief executive officer in Q1 2027.

Swartz, who previously served as chief business officer and chief operating officer at Voyager, joined the company in 2021. Before that, she spent 26 years at Genzyme Corporation and Sanofi Genzyme in roles spanning commercial, development, business operations, strategy, and finance.

Dr. Sandrock is expected to remain CEO until Voyager receives initial acute safety data from a clinical trial of VY1706, its

Voyager Therapeutics names Robin Swartz president, plans CEO shift

Wed, 21 Oct 2026 08:02:16 -0400

Dr. Sandrock is expected to remain CEO until Voyager receives initial acute safety data from a clinical trial of VY1706, its

Voyager Announces CEO Succession Plan, Appoints Robin Swartz President

Wed, 21 Oct 2026 08:01:00 -0400

- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 -

- Dr. Sandrock expected to remain CEO through initial acute safety data with VY1706, anticipated in Q1 2027 pending enrollment, and to subsequently continue as a member of Voyager’s Board of Directors -

LEXINGTON, Mass., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that its Board

Voyager Announces CEO Succession Plan, Appoints Robin Swartz President

Wed, 21 Oct 2026 08:01:00 -0400

- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 -

H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR)

Thu, 27 Aug 2026 07:08:50 -0400

H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $25.00 price target on Voyager Therapeutics (NASDAQ: VYGR).

The analyst commented: "On August 21, we hosted an H.C. Wainwright At Home virtual fireside chat with Voyager Therapeutics' Chief Executive Officer Alfred Sandrock, covering the two wholly owned tau programs in Alzheimer's disease, the TRACER capsid and ALPL NeuroShuttle platforms, the partnered portfolio, and business development strategy. Both wholly owned programs are on track for 4Q26 inflection: tau positron emission tomography (PET) imaging efficacy data from the fully enrolled 52-patient Phase 1 multiple ascending dose (MAD) trial evaluating the anti-tau antibody

Form SCHEDULE 13G/A Voyager Therapeutics, Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26926474.html

Form SCHEDULE 13G/A Voyager Therapeutics, Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26926474.html

Voyager Therapeutics (VYGR) Tops Q2 EPS by 10c

Thu, 06 Aug 2026 17:34:22 -0400

Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $3.17 million versus the consensus estimate of $4.74 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

Form 8-K Voyager Therapeutics, For: Aug 06

Thu, 06 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26883403.html

Form 8-K Voyager Therapeutics, For: Aug 06

Thu, 06 Aug 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26883403.html

Form 10-Q Voyager Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883336.html

Form 10-Q Voyager Therapeutics, For: Jun 30

Thu, 06 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260806/26883336.html

Voyager Reports Second Quarter 2026 Financial and Operating Results